Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer

被引：0
作者：
Gwen M. H. E. Dackus
Katarzyna Jóźwiak
Elsken van der Wall
Paul J. van Diest
Michael Hauptmann
Sabine Siesling
Gabe S. Sonke
Sabine C. Linn
机构：
[1] Netherlands Cancer Institute,Division of Molecular Pathology
[2] University Medical Center Utrecht,Department of Pathology
[3] Netherlands Cancer Institute,Department of Epidemiology and Biostatistics
[4] Institute of Biostatistics and Registry Research,Division of Internal Medicine and Dermatology
[5] Brandenburg Medical School Theodor Fontane,Department of Research and Development
[6] University Medical Center Utrecht,Department of Health Technology & Services Research, Technical Medical Center
[7] Netherlands Comprehensive Cancer Organisation The Netherlands,Department of Medical Oncology
[8] University of Twente,undefined
[9] Netherlands Cancer Institute,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 185卷
关键词：
Breast cancer; Human epidermal growth-factor receptor 2; Adjuvant treatment; Trastuzumab; Concurrent; Sequential;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：817 / 830
页数：13
相关论文
共 446 条
  • [1] Perez EA(2011)Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer J Clin Oncol 29 4491-4497
  • [2] Suman VJ(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684
  • [3] Davidson NE(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273-1283
  • [4] Gralow JR(2009)Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial J Clin Oncol 27 6129-6134
  • [5] Kaufman PA(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
  • [6] Visscher DW(2007)2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29-36
  • [7] Chen B(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-244
  • [8] Ingle JN(2009)Breast cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw 7 122-192
  • [9] Dakhil SR(2017)Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: results from the SIGNAL/PHARE prospective cohort Eur J Cancer 81 151-160
  • [10] Zujewski J(2019)Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger Ann Oncol 30 1194-1220
12345678910